Formulation Development of an Antifibrin Monoclonal Antibody Radiopharmaceutical
These studies have shown that formulation development of a monoclonal anti-body radio-immunoscintigraphy agent is a challenging task involving a number of issues related to the radiochemistry of labeling as well as the stability of the antibody. Through a systematic approach, as described in this study, a stable and efficacious product of high quality can be developed in a rational and efficient manner. In developing an optimized formulation of Tc-99m—antifibrin Fab’ for use in immuno-scintigraphy of DVT, a number of critical components were examined in regard to technetium-labeling chemistry and the ability of the formulation to support the long-term stability of the product. It was found that the addition of glucarate as a transfer ligand, SnCl2 as a reducing agent, and neutral-to-acidic pH of the solution were essential for optimum radiolabeling of 0.5 mg of antifibrin Fab’ to a desired activity of 25 mCi of Tc-99m. The lyophilization of the final product was also required to further stabilize both the antifibrin Fab’ fragment and the reducing agent. The addition of carbohydrate as bulking agent and lyoprotectant and inclusion of EDTA as a chelating agent further improved the performance of the formulations, resulting in products with long shelf-life.
Many of the principles described in this study are not only useful in developing a technetium-based immunoscintigraphic agent but are also applicable to other immunopharmaceuticals, including products involving delivery of radionuclides, drugs, and toxins for immunotherapy of cancer and other diseases.
Unable to display preview. Download preview PDF.
- Eckelman, W. C., Paik, C. H., and Steigman, J., 1989, Three approaches to radiolabeling antibodies with 99mTc, Nucl. Med. Biol. 16:171–176.Google Scholar
- Goldenberg, D., Wlodkowski, T, Sharkey, R., Silberstein, E., Serafini, A., Garty, I., Van Heertum, R. L., Higginbolham-ford, E., Kotler, J., Balasubramaniam, N., Swayne, L., Hansen, H., and Pinsky, C., 1993, Colorectal cancer imaging with iodine-123-labeled CEA monoclonal antibody fragments, J. Nucl. Med. 34:61–70.PubMedGoogle Scholar
- Paik, C. H., Eckelnian, W., and Reba, R., 1986, Transchelation of 99mTc from low affinity sites to high affinity sites of antibody, Nucl. Med. Biol. 13:369–362.Google Scholar
- Pak, K. Y., Nedelman, M. A., Fogler, W. E., Tarn, S. H., Wilson, E., Van Haarlem, L. J. M., Colognola, R., Warnaar, S. A., and Daddona, P. E., 1991, Evaluation of the 323/A3 monoclonal antibody and the use of technetium-labeled 323/A3 Fab’ for the detection of Pan adenocarcinoma, Nucl. Med. Biol. 18:483–497.Google Scholar
- Rhodes, B., 1991, Direct labeling of proteins with 99m-Tc, Nucl. Med. Biol. 18: 667–676.Google Scholar
- Robyt, J. F, Ackerman, R. J., and Chitrenden, C. G., 1971, Reaction of protein disulfide groups with Ell-man’s reagent: a case study of the number of sulfhydryl and disulfide groups in asporgillus oryzaedamylase, papaine, and lysozyme, Arch. Biochem. Biophys. 147:262–269.CrossRefPubMedGoogle Scholar